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ValidationAbstract Green RP-HPLC method for a rapid analysis of olmesartan medoxomil (OLM) in bulk
drugs, self-microemulsifying drug delivery system (SMEDDS) and marketed tablets was developed
and validated in the present investigation. The chromatographic identiﬁcation was achieved on
Lichrosphere 250 · 4.0 mm RP C8 column having a 5 lm packing as a stationary phase using a
combination of green solvents ethyl acetate:ethanol (50:50% v/v) as a mobile phase, at a ﬂow rate
of 1.0 mL/min with UV detection at 250 nm. The proposed method was validated for linearity,
selectivity, accuracy, precision, reproducibility, robustness, sensitivity and speciﬁcity. The utility
of the proposed method was veriﬁed by an assay of OLM in SMEDDS and commercial tablets.
The proposed method was found to be selective, precise, reproducible, accurate, robust, sensitive
and speciﬁc. The amount of OLM in SMEDDS and commercial tablets was found to be
101.25% and 98.67% respectively. The proposed method successfully resolved OLM peak in the
presence of its degradation products which indicated stability-indicating property of the proposed
method. These results indicated that the proposed method can be successfully employed for a
routine analysis of OLM in bulk drugs and commercial formulations.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The pursuit in the ﬁeld of green chemistry is growing dramat-
ically and is becoming a grand challenge for chemists to devel-
op new products, processes and services that achieve the
necessary social, economical and environmental objectives
due to an increased cognizance of environmental safety,
S778 N. Haq et al.checking environmental pollution, sustainable industrial ecol-
ogy and cleaner production technologies worldwide. Many sol-
vents used in the analytical methodologies are volatile organic
compounds (VOCs), that are hazardous air pollutants (HAPs),
ﬂammable, toxic and/or carcinogenic [e.g., the majority of ana-
lytical methods certiﬁed by the US Environmental Protection
Agency (EPA) and Food and Drug Administration (FDA)
use corrosive and toxic chemicals, with no other options cur-
rently available] (Garrigues et al., 2010). They also pose seri-
ous environmental, health, and safety (EHS) concerns,
including human and eco-toxicity issues, process safety haz-
ards, and waste management issues.
Olmesartan medoxomil (OLM) is chemically 2,3 dihydroxy-2-
butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-
5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate
as shown in Fig. 1 (Celebier and Altinoz, 2007a).
It is an ester prodrug which metabolizes to its active metab-
olite olmesartan (OL) after in vivo absorption (Bari and Rote,
2009). Pharmacologically, it belongs to angiotensin II receptor
antagonist which is used in the treatment of hypertension
either alone or in combination with other antihypertensive
agents (Celebier and Altinoz, 2007a; Qutab et al., 2009;
Amudhavalli et al., 2011).
An extensive literature survey revealed that many analytical
methods have been reported for the analysis of OLM either
alone or in combination with other antihypertensive drugs in
pure drugs, marketed tablets and biological ﬂuids. Several high
performance liquid chromatography (HPLC) methods were re-
ported for the analysis of OLM alone or in combination with
other antihypertensive agents in pure drugs or tablet dosage
forms (Patel et al., 2007; Sagirli et al., 2007; Bari and Rote,
2009; Bajerski et al., 2008; Murakami et al., 2008; Sultana
et al., 2008; Birajdar et al., 2009; Rane et al., 2009; Sharma
and Pancholi, 2009; Trivedi et al., 2009; Qutab et al., 2009;
Godse et al., 2010; Kamble et al., 2010; Patil et al., 2010;
Amudhavalli et al., 2011; Rao et al., 2012). Some spectropho-
tometric methods have also been reported for the quantitative
analysis of OLM alone or in combination with other antihy-
pertensive agents in pure drugs or pharmaceutical formula-
tions (Celebier and Altinoz, 2007b; Patel et al., 2007; Bhosari
et al., 2009; Hemke et al., 2010; Rote and Bari, 2010; Darwish
et al., 2012). High performance thin layer chromatographyFigure 1 Chemical structure of OLM.(HPTLC) methods were also recorded for the analysis of
OLM in tablet dosage forms (Shah et al., 2007; Bari and Rote,
2009; Kadukar et al., 2009; Kamble et al., 2010; Moussa et al.,
2011). Ultra performance liquid chromatography (UPLC)
methods have also been reported for quantiﬁcation of OLM
in pharmaceutical formulations (Kumar et al., 2012; Raj
et al., 2012). The capillary zone electrophoretic (CZE) method
was also used for the quantitative analysis of OLM in tablet
dosage forms (Celebier and Altinoz, 2007b). Some analytical
techniques like HPLC (Sultana et al., 2008; Tambe et al.,
2010), HPTLC (Tambe et al., 2010) and liquid chromatogra-
phy–mass spectrometry [LCMS] (Liu et al., 2007; Vaidya
et al., 2008; Liu et al., 2010; Sengupta et al., 2010) methods
have also been reported for the quantiﬁcation of OLM in var-
ious biological ﬂuids like plasma, serum and urine.
On analyzing the scientiﬁc articles of the past several years
available for the assay of OLM, it becomes clear that organic
and mixed aqueous-organic solvent systems have been found
most useful for its analysis. Majority of these solvents are vol-
atile organic compounds and pose a threat to the environment
as they form low-level ozone and smog through free radical
air-oxidation processes. The main goal of the green analytical
chemistry is to take into consideration the amount and the tox-
icity of reagents consumed, and, consequently, the volume and
the toxicity of wastes generated during method development
and selection, thus reducing the environmental impact of the
activities of analytical chemistry (Anastas and Warner, 1998;
Sheldon, 2005). Green solvents or biosolvents are more an
environment-friendly alternative to petrochemical solvents,
which are derived from the processing of agricultural crops,
for example, ethyl acetate and ethanol.
To our surprise, in spite of several favorable features such
as non-toxicity, non-inﬂammability, non-aggressiveness, high
biodegradability and cost effectiveness, the full potential of
environmentally benign solvents (and their combinations) as
eluents for the analysis of drugs/pharmaceuticals has not been
exploited (Salvador and Chisvert, 2001; Vidotti et al., 2006).
To our knowledge, the stability-indicating green reverse
phase HPLC (RP-HPLC) method using environmentally be-
nign eluents (ethyl acetate and ethanol) has not been reported
in the literature for the analysis of OLM in pharmaceutical for-
mulations and biological ﬂuids. Therefore, the aim of the pres-
ent study was to develop and validate a simple, cost effective,
rapid, facile, selective, precise, reproducible, accurate, robust
and stability-indicating green RP-HPLC method coupled with
UV detection for the rapid analysis of OLM in the self-micro-
emulsifying drug delivery system (SMEDDS) and marketed
tablets utilizing a combination of ethyl acetate and ethanol
(50:50) as mobile phase and isocratic elution, taking into con-
sideration a variety of international conference on harmoniza-
tion (ICH) recommended test conditions (ICH, 2003).
The novelty of this method is that it used an environmen-
tally benign mobile phase (ethyl acetate and ethanol) with C8
RP-HPLC column for the rapid analysis of OLM. The devel-
oped method would also be utilized for studying the stability
of OLM in various commercial and in-house developed phar-
maceutical formulations.
Moreover, this study is advantageous because it protects
analytical scientists and chemists from the exposure to volatile
and corrosive organic solvents during experimentation.
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2.1. Chemicals and reagents
OLM (purity 99.2%) was obtained as a gift sample from Alfa
Aesar, A Johnson Metthey Company (Ward Hill, MA). HPLC
grade ethyl acetate and ethanol, hydrochloric acid, sodium
hydroxide and hydrogen peroxide were purchased from BDH
Laboratory supplies (Liverpool, UK). All other chemicals and
reagents used were of analytical reagent (AR) grade. Commer-
cial tablets were purchased from the local market of Riyadh,
Saudi Arabia. OLM SMEDDS was prepared in the laboratory
by the reported method using Capryol-90 as the oil phase,
Tween-20, Tetraglycol, and distilled water as surfactant, cosur-
factant and aqueous phase respectively (Lee et al., 2009).
2.2. Instrumentation and chromatographic conditions
Chromatographic identiﬁcation was performed at room tem-
perature (25 ± 1 C), with Waters HPLC system (Waters,
USA) equipped with a model 600 LC pump, model 717 auto-
sampler, quaternary LC-10A VP pumps, a programable UV–
visible variable-wavelength detector, SPD-10AVP column
oven, a SCL 10AVP system controller (Shimadzu, Japan)
and a vacuum degasser was used. The software used in the
system was Millennium, version 32. The chromatographic
identiﬁcation was achieved on a Lichrosphere 250 · 4.6 mm
RP C8 column (Phenomenex, USA) having a 5 lm packing
as a stationary phase. The green solvents ethyl acetate:ethanol
(50:50% v/v) was used as an environmentally benign mobile
phase. The elution was performed at a ﬂow rate of
1.0 mL/min with UV detection at 250 nm. Samples (10 lL)
were injected using a Waters auto sampler.
2.3. Preparation of drug stock solution for calibration curve
Calibration curve for OLM was prepared in the range of 0.1–
200 lg/mL. Stock solution of 200 lg/mL concentration was
prepared by dissolving 20 mg of OLM in a mobile phase. Serial
dilutions from this stock solution were made by diluting the re-
quired aliquots with a mobile phase to get the concentration in
the range of 0.1–200 lg/mL.
2.4. Method development
The selection of the solvent system was decided on the basis of
the sensitivity of the assay, suitability for stability studies, time
required for the analysis, peak parameter, ease of preparation
and availability of cost effective green solvents. Based on the
above criterion, we had tried ethanol, ethyl acetate, ethanol–
water, ethyl acetate–ethanol, Tween-80, Tween 80–water,
glycerol and glycerol–water alone as well as at different pro-
portions. Out of the tried mobile phases for chromatographic
identiﬁcation, the environmentally benign combination of
ethyl acetate and ethanol (50:50% v/v) was selected as the ﬁnal
mobile phase for further studies.
2.5. Validation studies
The proposed green RP-HPLC method was validated accord-
ing to ICH guidelines for the linearity, selectivity, accuracy,precision, reproducibility, sensitivity, robustness and
speciﬁcity.
Freshly prepared linearity solutions of different concentra-
tions (0.1–200 lg/mL) were used for the construction of cali-
bration curves. The mobile phase (ethyl acetate:ethanol
50:50% v/v) was delivered at 1.0 mL/min for column equilibra-
tion; the baseline was monitored continuously during this pro-
cess. The detection was performed at 250 nm. The prepared
dilutions were injected in triplicates and peak areas were re-
corded for each dilution, and the concentration was plotted
against peak areas.
The selectivity of the green RP-HPLC method was deter-
mined by repeated injections of target concentration of OLM
(20 lg/mL). The variations in retention time and peak area
were recorded for selectivity determination.
Accuracy of the proposed method was determined by the
standard addition method. The standard OLM solution
(20 lg/ml) was spiked with 0, 50, 100 and 150% extra OLM
standard solution and were reanalyzed by the proposed meth-
od. Experiments were performed in triplicates. Recovery (%),
RSD (%), and standard error were calculated for each
concentration.
Precision of the green HPLC method was determined as
repeatability (intraday precision) and intermediate precision.
Repeatability studies were performed by an analysis of
four different concentrations of the drug (20, 30, 40 and
50 lg/mL) in triplicate on the same day. Intermediate precision
of the method was checked by repeating the studies on three
different days.
The reproducibility of the proposed method was evaluated
by determining intraday and intermediate precision on a differ-
ent instrument, analysis was performed by a different scientist
in a different laboratory. For both intraday and intermediate
variations, solutions of OLM at four different concentrations
(20, 30, 40 and 50 lg/mL) were analyzed in triplicate.
Detection (LOD) and quantiﬁcation (LOQ) limits of the
green HPLC method were determined by the standard devia-
tion (SD) method. For determination of LOD and LOQ, blank
samples (samples without OLM) were injected in triplicate and
the peak area of these blank samples was recorded. LOD and
LOQ were determined from the slope (S) of the calibration
curve and the standard deviation (SD) of the response by use
of the formulae LOD= 3.3 · SD/S and LOQ= 10 · SD/S.
The robustness of the green HPLC method was determined
to evaluate the effect of the deliberate variation of chromato-
graphic conditions on the determination of OLM. The target
concentration (20 lg/mL) was selected for these studies.
Robustness was determined by changing the mobile phase
composition from 50:50 to 45:55 and 55:45, ﬂow rate from
1.0 mL/min to 0.75 and 1.25 mL/min and wavelength of detec-
tion from 250 nm to 248 and 252 nm.
2.6. Forced degradation studies
In order to determine the stability-indicating property and
speciﬁcity of the green HPLC method, force degradation stud-
ies were performed at various stress conditions such as acid
stress, base stress, oxidative stress and thermal stress
conditions.
For acid and base-induced degradation, the target con-
centration (20 lg/mL) of OLM was freshly prepared into a
mobile phase for acid and base-induced degradation studies.
Figure 2 HPLC chromatogram of OLM in ethyl acetate:ethanol (50:50% v/v) with retention time of 2.13 min.
Table 1 Linear regression data for the calibration curves of
OLM (n= 3).
Parameters Values
Linearity range 0.1–200 lg/ml
Correlation coeﬃcient (r2 ± SD) 0.999 ± 0.0005
Regression equation y= 9930x–19117
Slope ± SD 9930.00 ± 45.32
Conﬁdence interval of slope* 9817.43–10042.56
Standard error of slope 26.16
Slope without intercept ± SD 9760.50 ± 39.14
Intercept ± SD 19117.00 ± 561.37
Conﬁdence interval of intercept* 17722.32–20511.64
Standard error of intercept 324.11
* 95% conﬁdence interval.
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and base hydrolysis by adding 4 mL of 1 M HCl and 4 mL
of 1 M NaOH, respectively. These mixtures were kept in a
hot air oven for 48 h at 50 C and then reanalyzed by the
green HPLC method for the determination of OLM in the
presence of its acid and base degradation products
respectively.Table 2 Selectivity of the green HPLC method (n= 6)
S. no. Concentration (lg/ml) Peak Area Mean area ±
1 185431
2 176543
3 20 172376 180239 ± 205
4 182312
5 179865
6 191412For oxidative degradation, the target concentration (20 lg/
mL) of OLM was prepared into a mobile phase for oxidative
degradation studies. An aliquot of this solution (20 lg/mL)
was exposed to oxidative degradation by adding 4 mL of
30% hydrogen peroxide (H2O2). This mixture was kept in
the hot air oven for 48 h at 50 C and then analyzed by the
green HPLC method for the determination of OLM in the
presence of its oxidative degradation products.
For thermal degradation, an aliquot of target solution
(20 lg/mL) was exposed to thermal degradation by expos-
ing it in the hot air oven for 48 h at 50 C and then
analyzed by the green HPLC method for the determina-
tion of OLM in the presence of its thermal degradation
products.
2.7. Solution stability studies
To ensure the reliability of the results in relation to handling
and storage of stock standards, solution stability studies were
performed at the target concentration (20 lg/mL) by a re-
peated analysis of the samples over a period of 72 h at ambient
temperature (25 ± 1 C) and at the refrigerated temperature
(4 ± 0.5 C)..
SD RSD (%) Rt (min) Mean Rt ± SD (% RSD)
2.13
2.14
0 1.13 2.13 2.14 ± 0.011 (0.51)
2.15
2.14
2.16
Table 3 Accuracy of the green HPLC method (% recovery, n= 3).
% of Drug added to
analyte
Theoretical
concentration (lg/ml)
Measured concentration (lg/
ml) ± SD
RSD
(%)
Standard
error
%
Recovery
0 20 19.66 ± 0.26 1.32 0.15 98.30
50 30 30.52 ± 0.54 1.76 0.31 101.73
100 40 40.32 ± 0.77 1.90 0.44 100.80
150 50 49.01 ± 0.85 1.74 0.49 98.02
Table 4 Precision of the green HPLC method (n = 3).
Concentration (lg/ml) Repeatability (intra-day precision) Intermediate precision (inter-day)
Mean area ± SD RSD (%) Standard error Mean area ± SD RSD (%) Standard error
20 184346 ± 1134 0.61 654 172814 ± 1814 1.04 1047
30 271151 ± 1532 0.56 884 268978 ± 2032 0.75 1173
40 373214 ± 2832 0.75 1635 367865 ± 3725 1.01 2150
50 441087 ± 3498 0.79 2019 445432 ± 4172 0.93 2408
Table 5 Reproducibility of the green HPLC method (n= 3).
Concentration (lg/ml) Repeatability (Intra-day precision) Intermediate precision (Inter-day)
Mean area ± SD RSD (%) Standard error Mean area ± SD RSD (%) Standard error
20 178415 ± 1321 0.74 762 170487 ± 2098 1.23 1211
30 268743 ± 1765 0.65 1019 264321 ± 2243 0.84 1295
40 370145 ± 3045 0.82 1758 364217 ± 3813 1.04 2201
50 437654 ± 3765 0.86 2173 441987 ± 4278 0.96 2469
Table 6 Robustness of the green HPLC method (n= 3).
Parameters Mean area ± SD RSD (%) Standard error Retention time ± SD RSD (%) Standard error
Mobile phase composition
(55:45% v/v) 178751 ± 1605 0.89 926.67 2.16 ± 0.02 1.06 0.011
(45:55% v/v) 175108 ± 1819 1.03 1050.23 2.18 ± 0.01 0.52 0.005
Mobile phase ﬂow rate
(1.25 ml/min) 181043 ± 2213 1.22 1277.71 2.01 ± 0.02 1.14 0.011
(0.75 ml/min) 177876 ± 2341 1.31 1351.61 2.25 ± 0.03 1.37 0.017
Detection wavelength (nm)
248 169032 ± 2554 1.51 1474.59 2.13 ± 0.02 1.09 0.011
252 185421 ± 2672 1.44 1542.72 2.14 ± 0.03 1.63 0.017
Table 7 Results of forced degradation studies of OLM at various stress conditions (n= 3).
Stress condition Mean area ± SD RSD (%) Standard
error
Number of
degradation
products (Rt)
OLM
remaining (lg/ml)
OLM
recovered (%)
1 M HCl 125632 ± 1542 1.22 890 1 (2.74) 14.57 72.85
1 M NaOH 61234 ± 623 1.01 359 1 (2.98) 8.09 40.45
30% H2O2 41234 ± 432 1.04 249 2 (0.84, 2.97) 6.07 30.35
Thermal 107613 ± 1231 1.14 710 1 (2.51) 12.76 63.80
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SMEDDS and marketed tablets
SMEDS formulation of OLM was prepared in the laboratory
by the reported method using Capryol-90, Tween-20, Tetragly-
col and distilled water as the oil phase, surfactant, cosurfactantand aqueous phase respectively (Lee et al., 2009). To determine
the OLM content in SMEDDS (containing 20 mg/mL of OLM),
1 mL of SMEDDS was suitably diluted with the mobile phase to
obtain 100 mL of stock solution. This solution was sonicated for
10 min then analyzed for drug content after suitable dilution
with the mobile phase. The sample obtained was analyzed for
Figure 3 HPLC chromatogram of OLM in the presence of 1 M HCl.
Figure 4 HPLC chromatogram of OLM in the presence of 1M NaOH.
S782 N. Haq et al.drug content. The possibility of interference of SMEDDS com-
ponents present in the formulation was studied. For the determi-
nation of the content of OLM in marketed tablets, 100 mL stock
of each formulation was prepared and analyzed for drug content
using the same procedure as used for SMEDDS.
3. Results and discussion
3.1. Method development
With the background to develop an environmentally benign
RP-HPLC method for the rapid analysis of OLM in SMEDS
and marketed tablets, various solvent systems as mobile phases
were tried for the development of a green and environmentally
benign RP-HPLC method for the rapid analysis of OLM.
During the method development step, use of ethanol or
ethyl acetate or Tween-80 or glycerol alone as the mobile phaseresulted in an asymmetric peak with a greater tailing factor
(2.3) and a less number of theoretical plates. Further,
Tween-80-water, ethanol–water and glycerol–water were tried
at different proportions at a ﬂow rate of 1.0 mL/min. A chro-
matograph was obtained with a very poor peak with greater
asymmetry. In order to get a sharp peak with an asymmetry
factor less than 2 and good sensitivity, ethyl acetate-ethanol
as another mobile phase was tried. The detection wavelength
for the analysis of OLM was set at 250 nm as reported previ-
ously (Murakami et al., 2008). The combination of ethyl ace-
tate and ethanol (50:50% v/v) was found to be better with
sharp peak, suitable retention time and good tailing factor/
asymmetry (1.09). Therefore, this combination was selected
as the ﬁnal mobile phase to obtain a rapid and simple assay
method for OLM with a reasonable run time (5 min), suitable
retention time (2.31 ± 0.005 min) and the acceptable tailing or
asymmetry factor (Fig. 2).
Figure 5 HPLC chromatogram of OLM in the presence of 30% H2O2.
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The calibration curve of the standard OLM was evaluated by
the linear least square analysis. The calibration curve of peak
area versus concentration was found to be linear in the concen-
tration range of 0.1–200 lg/mL. The equation for the calibra-
tion curve was y = 9930x–19117. The correlation coefﬁcient
(r2) of the calibration curve was found to be 0.999 ± 0.0005
(Table 1). The linear regression data for the calibration curve
of OLM are shown in Table 1.
The selectivity of the green HPLC method was determined
by repeated injections of OLM. The values of SD and % RSD
in retention time and peak area were found to be very low (Ta-
ble 2). The % RSD in retention time and peak area was found
to be 0.38 and 1.13, respectively which indicated the selectivity
of the green HPLC method.
The accuracy of the green HPLC method was determined
as % recovery and is shown in Table 3. Good recoveries
(98.02–101.73%) of the spiked drug were obtained at each con-
centration level. The standard deviation values at each concen-
tration level were found be very low (0.26–0.85). The % RSD
(1.32–1.90%) and standard error (0.15–0.49) of the method
were also found to be very low which indicated the accuracy
of the proposed method.
The results of intraday precision and interday/intermediate
precision were expressed in terms of % RSD and are shown in
Table 4. The developed method was found to be precise as the
% RSD values for intraday and intermediate precision studies
were found in the range of 0.56–0.79 and 0.93–1.04 respec-
tively. Low value of % RSD is the indication of precision of
the proposed method.
Reproducibility was evaluated by determining the precision
of the proposed method in a different laboratory on a different
Waters HPLC instrument with the analysis carried out by an-
other person. Both intraday and intermediate precision weredetermined. No signiﬁcant differences between RSD (%)
values for intraday and intermediate precision were
observed, which indicated the reproducibility of the method
(Table 5).
LOD and LOQ for the proposed method were determined by
the standard deviation of the blank response. The values of LOD
and LOQ were found to be 0.06 and 0.18 lg/mL, respectively,
which indicated the sensitivity of the proposed method.
For robustness, the SD, % RSD and standard error of the
peak areas for the mobile phase composition, wavelength of
detection and ﬂow rate at a concentration level of 20 lg/mL
are shown in Table 6. The low values of % RSD and standard
error obtained after introducing small deliberate changes in the
mobile phase composition, wavelength of detection and ﬂow
rate indicated the robustness of the proposed method.
3.3. Forced degradation studies
The stability-indicating property and speciﬁcity of the green RP-
HPLC method was determined by exposing a target concentra-
tion of OLM (20 lg/mL) under various stress conditions.
OLM was found to be degraded extensively under all stress con-
ditions. Under acid stress conditions, 72.85% of OLM was
remaining and 27.15% was degraded (Table 7 and Fig. 3). There-
fore, OLM was found to be sufﬁciently unstable under acidic
conditions. The acid-induced degradation products (peak 2 in
Fig. 3) were found to be eluted with a retention time of 2.74 min.
However, under base stress conditions, only 40.45% of
OLM was remaining and 59.55% was degraded (Table 7).
The base-induced degradation products (peak 2 in Fig. 4) were
found to be eluted with a retention time of 2.98 min.
The drug was also found to be degraded sufﬁciently under oxi-
dative stress conditions (30% H2O2) (Fig. 5). The H2O2-induced
degradation products (peak 1 and 3 in Fig. 5) were found to be
eluted with a retention time of 0.84 and 2.97 min, respectively.
Figure 6 HPLC chromatogram of OLM under thermal condition.
S784 N. Haq et al.However under thermal stress conditions, 63.80% of OLM
was remaining and only 36.20% was degraded. The thermal-
induced degradation product (peak 2 in Fig. 6) was found to
be eluted with a retention time of 2.51 min.
Overall these results indicated that the proposed HPLC
method was speciﬁc and stability-indicating.
Solution stability.
OLM was found to be stable when stored for 72 h at ambi-
ent temperature (25 ± 1 C) and under refrigeration
(4 ± 0.5 C) in a combination of green ethyl acetate and etha-
nol (mobile phase). More than 99% of the OLM remained un-
changed, on the basis of comparison of peak areas with those
obtained from a freshly prepared solution of OLM.
3.4. Application of the proposed method for assay of OLM in
SMEDDS and marketed tablets
The green RP-HPLC method developed was found to be ra-
pid, selective, sensitive and suitable for the quantitative deter-
mination of OLM. Therefore this method was applied for the
quantitative analysis of OLM in SMEDDS and marketed tab-
lets. The amount of OLM in SMEDDS was found to be
101.25 ± 1.12%. Whereas, the amount of OLM in marketed
tablets was found to be 98.67 ± 1.21%. These assay values
were found within the range of ICH guidelines (98–102%).
High assay values of OLM in SMEDDS and marketed tablets
suggested that the method could be suitable for the routine
analysis of OLM in various pharmaceutical formulations.
The chromatogram of OLM extracted from the SMEDDS
and marketed tablet was matching with that of pure OLM,
showing the purity of peak in both formulations. There was
no interaction between OLM and various excipients present
in commercial tablets or SMEDDS formulation.
4. Conclusion
The proposed RP-HPLC method is simple, selective, rapid,
accurate, precise, reproducible, robust, sensitive and stability-
indicating. Therefore, the method was applied to the assay ofOLM in SMEDDS and commercial tablets. A high assay value
was obtained in both of the formulations. The method is also
simple in terms of sensitivity, use of an environmentally benign
mobile phase, lack of extraction procedures, lower retention
time (rapid analysis), no internal standard and UV detection.
All these factors make this method superior for the routine
analysis of OLM in bulk drugs and various commercially
available formulations of OLM. The method could also be ap-
plied for the prediction of shelf life in pharmaceutical formula-
tions having OLM as an active ingredient because it is having
stability-indicating properties. The replacement of widely-used
traditional solvents and chemicals with new, innocuous, and
less toxic ones provides environmentally benign alternatives
to the more hazardous chemicals and processes in the ﬁeld
of drug/pharmaceutical analysis.
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